Anthem Biosciences

    ANTHEM
    Pharma
    ₹914.35
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹51,526 Cr

    P/E
    84.51
    Day range
    ₹907.55 – ₹923.70
    52-week range
    ₹579.15 – ₹989.10
    Volume
    2.92 L
    Open
    ₹916.20
    Prev close
    ₹924.25

    Latest results · Q2 FY27(consolidated)Revenue ₹594 Cr+8.0%Profit ₹211 Cr+21.9%Margin 35.6%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      71.40%, down 3.29 pts since 2025-09-30 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 64 / 100

    Factor percentiles

    Value23
    Quality85
    Momentum75
    Low volatility74

    Derived metrics

    Earn. yield
    1.2%
    Graham no.
    ₹119.68
    vs Graham
    -86.9%
    ROE ÷ P/B
    1.3%
    12-1 mom.
    +16.6%
    Return / vol
    1.01
    Magic Formula
    #342
    Piotroski
    5/6
    FCF yield
    1.2%
    PEG
    3.85

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Anthem BiosciencesANTHEM₹51,526 Cr84.5116.1021.7%30.0%46.0%0.01+8.0%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 3h ago

    Headlines about Anthem Biosciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    81.6
    Price / Book
    15.71
    ROE (FY26)
    21.7%
    ROCE (latest year)
    30%
    Dividend yield
    0.22%

    Moving averages (NSE)

    20-day
    ₹876.9
    Price above
    50-day
    ₹884.41
    Price above
    200-day
    ₹784.44
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +26.2%
    Profit 3Y CAGR
    +15.4%
    Revenue YoY (Sep 2026)
    +8.0%
    Profit YoY (Sep 2026)
    +22.0%
    Operating margin
    46.0%
    Net margin
    35.5%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr800 Cr
    • Revenue
    • Net profit

    Operating margin

    Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%25%50%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2019 (S)Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY20FY21FY22FY23FY24FY25FY260%20%40%60%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019 (S)Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x0.5x1x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales339525498483540550423611418594
    YoY Sales growth——————-15—-23—
    Expenses218330338288349332266344268323
    Operating Profit121195160195191218157267151271
    OPM %36%37%32%40%35%40%37%44%36%46%
    Other Income1928241423488522559
    Interest4431230213
    Depreciation19202030263435403031
    Profit before tax118200161178186230130278145296
    Tax %30%19%23%54%27%24%29%32%17%29%
    Net Profit821621248313617393190120211
    EPS in Rs₹1.47₹2.88₹2.21₹1.47₹2.42₹3.09₹1.65₹3.38₹2.13₹3.75

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days101

    +17 days since Mar 2021

    Inventory Days56

    +27 days since Mar 2021

    Days Payable34

    -16 days since Mar 2021

    Cash Conversion Cycle124

    +61 days since Mar 2021

    Working Capital Days92

    +65 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients. [1]

    Strengths

    • Company has reduced debt.
    • Company is almost debt free.
    • Company's working capital requirements have reduced from 118 days to 92.3 days

    Risks

    • Stock is trading at 15.7 times its book value

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +14%
    3 Years
    +26%
    TTM
    -1%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +17%
    3 Years
    +21%
    TTM
    +22%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    —
    1 Year
    +42%

    Return on Equity

    10 Years
    —
    5 Years
    +23%
    3 Years
    +21%
    Last Year
    +22%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter74.69%74.67%71.42%71.39%-0.03 pp
    FII1.37%1.28%2.57%3.79%+1.22 pp
    DII7.60%11.55%13.48%12.10%-1.38 pp
    Public16.34%12.48%12.52%12.71%+0.19 pp

    Filed with NSE for Sept 2026: promoters 71.40%, public 28.60%

    Analysts & fund holdings

    100%
    100% recommend buy
    8 analysts cover the stock
    Valuation vs Biotechnology
    P/E84.5 vs 45.2
    Sector P/B6.05

    Who holds the shares, quarter by quarter

    Mutual funds 9.25% (-1.90 pp)
    Jul 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters71.4%
    • Foreign institutions3.8%
    • Mutual funds9.3%
    • Insurance1.7%
    • Other domestic institutions1.1%
    • Retail1.8%
    • Others10.9%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Flexi Cap Fund1.15%0.56%-0.05 pp
    SBI Midcap Fund0.68%1.61%+0.17 pp
    Axis Midcap Fund0.51%0.80%+0.40 pp
    Axis ELSS-Tax Saver Fund0.46%0.80%+0.07 pp
    Aditya Birla SL Flexi Cap Fund0.39%0.72%+0.01 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    29.3%
    Downside volatility
    25.6%
    Worst 5% of days
    2.7%
    Average of that tail
    3.4%
    Max drawdown (1Y)
    31.5%
    Below its peak
    4.6%

    Against the market

    Beta vs Nifty 50
    0.56
    Correlation
    0.26
    Relative strength (3M)
    -2.1%
    ATR (14)
    3.0%

    Return

    Return 1M
    +11.2%
    Return 3M
    +1.8%
    Return 6M
    +15.9%
    Return 1Y
    +29.7%
    vs 200-day average
    +16.6%

    Momentum

    RSI (14)
    57.6
    MACD histogram
    6.08
    Stochastic %K
    56.0
    ADX (14)
    29.1
    +DI / −DI
    29.3 / 18.7
    Money flow index
    67.2

    Participation

    Delivery (20d avg)
    52.1%
    vs its 60-day baseline
    -2.1 pts
    Volume vs 20-day
    -0.4σ
    Close vs day's VWAP
    -0.0%
    52-week position
    88 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    ₹633 Cr
    FCF yield
    1.2%
    Cash conversion
    1.43
    Accruals ratio
    -0.074
    Net debt
    ₹21 Cr
    Net debt / equity
    0.01
    EV / sales
    25.19
    PEG
    3.85
    Capex intensity
    9.9%
    Revenue CAGR
    8.0%
    Profit CAGR
    21.9%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹1338 Cr
    1 buys · ₹0
    3 sells · ₹1338 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Viridity Tone LLP
    Designated Person · Market Sale
    Sell9,00,000₹82.7 Cr21 Sept 2026
    Viridity Tone LLP
    Other · Market Sale
    Sell2,03,13,795₹1255 Cr12 Mar 2026
    Aruna Ganesh
    Promoter Group · Gift
    Buy85,57,302₹012 Mar 2026
    Krithika Ganesh
    Promoter Group · Gift
    Sell85,57,302₹012 Mar 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹2.00

      Dividend - Rs 2 Per Share

      25 Jun 2026
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under Reg 74(5) of DP Regulations

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of closure of Trading Window for Q2FY27

    Company Update
    Settlement Of Upside Sharing Arrangement

    Intimation of the settlement of Upside Sharing Arrangement

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of Earnings Conference Call held on July 22, 2026.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Anthem Biosciences Limited has submitted the Exchange the voting results and a copy of scrutinizer report of the 20th Annual General Meeting of the Company held on July 22, 2026

    AGM/EGMPrice-sensitive
    Announcement Under

    Anthem Biosciences Limited has informed the Exchange regarding the Proceedings of the 20th Annual General Meeting held on Wednesday, July 22, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio recording of Earnings Call for the quarter ended June 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication on Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

    Revised Press Release on Unaudited Financial Results for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Revised Investor Presentation for Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release on Consolidated Financial Results for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation on Unaudited Consolidated Financial Results for the quarter ended June 30, 2026`

    Result
    Financial Results For The Quarter Ended June 30, 2026

    Financials Results for the quarter ended June 30, 2026

    Board Meeting
    Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday, July 21, 2026

    Outcome of the Board Meeting held on Tuesday, July 21, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Earnings Conference Call to discuss on Unaudited Standalone and Consolidated Financial Results for quarter ended June 30, 2026

    Filed with BSE (scrip 544449); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Anthem Biosciences: common questions

    Answered from the figures on this page.

    Anthem Biosciences last traded at ₹914.35 (NSE, as of 18 Nov 2026). The last session moved it down 1.07%.

    Anthem Biosciences is valued at about ₹51,526 crore (NSE, as of 18 Nov 2026).

    Anthem Biosciences trades at a price-to-earnings ratio of 84.51 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Anthem Biosciences has traded between ₹579.15 and ₹989.10 over the past 52 weeks, to 18 Nov 2026. It is currently 82% of the way up that range.

    Anthem Biosciences (ANTHEM) is classified under Pharma on this site's screener.